Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6209474

COC(=O)C1CCNCC1.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 1/20 0.45
GABRD O14764 1/20 0.45
GABRA1 P14867 1/20 0.45
TSHR P16473 1/20 0.45
GABRB1 P18505 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
GABRA4 P48169 1/20 0.45
GABRE P78334 1/20 0.45
PMP22 Q01453 1/20 0.45
GABRA6 Q16445 1/20 0.45
GABRG1 Q8N1C3 1/20 0.45
GABRG3 Q99928 1/20 0.45
GABRQ Q9UN88 1/20 0.45
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL29651364 1.00 GABRP (0.45) GABRPGABRDGABRA1TSHRGABRB1
SCHEMBL27030505 0.87 GABRP (0.52) GABRPGABRDGABRA1TSHRGABRB1
SCHEMBL5163 0.87 GABRP (0.52) GABRPGABRDGABRA1TSHRGABRB1
Potassium SCHEMBL31108386 0.85 CHRNB2 (0.50) GABRPGABRDGABRA1TSHRGABRB1
Hydrochloric Acid SCHEMBL27569873 0.85 CHRNB2 (0.50) GABRPGABRDGABRA1TSHRGABRB1
Bromide SCHEMBL11553713 0.85 CHRNB2 (0.50) GABRPGABRDGABRA1TSHRGABRB1
Hydrochloric Acid SCHEMBL774514 0.85 CHRNB2 (0.50) GABRPGABRDGABRA1TSHRGABRB1
Trifluoroacetic Acid SCHEMBL28659181 0.83 SMN1; SMN2 (0.47) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
Trifluoroacetic Acid SCHEMBL15551956 0.83 SMN1; SMN2 (0.51) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
Trifluoroacetic Acid SCHEMBL27039417 0.83 TSHR (0.42) GABRPGABRDGABRA1TSHRGABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556384-A2 PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-07-27 EP claimed
WO-2004018472-A2 PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2004-03-04 WO claimed
US-12145929-B2 Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same NEXTGEN BIOSCIENCE CO., LTD. (KR) 2024-11-19 US disclosed
US-20240279216-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME NEXTGEN BIOSCIENCE CO., LTD. (KR) 2024-08-22 US disclosed
EP-4353720-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME Nextgen Bioscience Co., Ltd. (KR) 2024-04-17 EP disclosed
CN-117396471-A Novel piperidine derivatives and pharmaceutical compositions for inhibiting autotaxin comprising the same 株式会社次代生物科学 2024-01-12 CN disclosed
WO-2023055178-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME 주식회사 넥스트젠바이오사이언스 2023-04-06 WO disclosed
CN-102030750-A Novel tetrahydro-1H-pyrido [4,3-b] indole derivatives as CB1' receptor ligands ASTRAZENECA AB 2011-04-27 CN disclosed
CN-101175754-A Novel tetrahydro-1H-pyrido [4, 3-b ] indole derivatives as CB1 receptor ligands ASTRAZENECA AB (SE) 2008-05-07 CN disclosed
EP-1556384-A2 PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-07-27 EP disclosed
WO-2004018472-A2 PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279216-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME ENPP2, UACA, ITCH GABRP 4310/4885GABRD 4795/4885GABRA1 4705/4885
US-12145929-B2 Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same ENPP2, UACA, ACAT2 GABRP 4087/4885GABRD 4714/4885GABRA1 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.